Login
Home
Charts
Search
Watchlist
Products

Medicamen Organics Ltd

MEDIORG·NSE
₹23.00+4.55%Wed, 23 Sept '26 15:31
Industry:Pharma - Formulators
Indices:

Medicamen Organics Ltd

MEDIORG
NSE
₹23.00
+4.55%
|Wed, 23 Sept '26 15:31
SOICxStockScans Reports
Industry
Pharma - Formulators
Indices
View
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
Financials
Documents
Shareholdings
Corporate Actions
Segments
Quick Ratios
Quarterly Results
Profit & Loss
Balance Sheet
Cash Flow
Ratios
Peer Comparison
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
₹34Cr
Close
Close Price
₹23.00
Industry
Industry
Pharma - Formulators
PE
Price To Earnings
—
PS
Price To Sales
1.51
Revenue
Revenue
₹23Cr
Rev Gr TTM
Revenue Growth TTM
-40.74%
PAT Gr TTM
PAT Growth TTM
-199.26%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Revenue
RevenueCr
11141722185
Growth YoY
Revenue Growth YoY%
46.754.77.5-77.8
Expenses
ExpensesCr
91214181412
Operating Profit
Operating ProfitCr
22343-7
OPM
OPM%
21.216.716.417.919.2-150.2
Other Income
Other IncomeCr
100000
Interest Expense
Interest ExpenseCr
000000
Depreciation
DepreciationCr
000000
PBT
PBTCr
32343-8
Tax
TaxCr
01111-1
PAT
PATCr
11232-6
Growth YoY
PAT Growth YoY%
11.0101.635.1-338.6
NPM
NPM%
12.09.09.111.811.4-126.8
EPS
EPS₹
0.00.01.52.21.7-5.2
QuarterSep 2023Mar 2024Sep 2024Mar 2025Sep 2025Mar 2026
Revenue
RevenueCr
11141722185
Growth YoY
Revenue Growth YoY%
46.754.77.5-77.8
Expenses
ExpensesCr
91214181412
Operating Profit
Operating ProfitCr
22343-7
OPM
OPM%
21.216.716.417.919.2-150.2
Other Income
Other IncomeCr
100000
Interest Expense
Interest ExpenseCr
000000
Depreciation
DepreciationCr
000000
PBT
PBTCr
32343-8
Tax
TaxCr
01111-1
PAT
PATCr
11232-6
Growth YoY
PAT Growth YoY%
11.0101.635.1-338.6
NPM
NPM%
12.09.09.111.811.4-126.8
EPS
EPS₹
0.00.01.52.21.7-5.2

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2024Mar 2025Mar 2026
Revenue
RevenueCr
253823
Growth
Revenue Growth%
51.1-40.7
Expenses
ExpensesCr
213226
Operating Profit
Operating ProfitCr
57-4
OPM
OPM%
18.817.3-16.6
Other Income
Other IncomeCr
000
Interest Expense
Interest ExpenseCr
111
Depreciation
DepreciationCr
111
PBT
PBTCr
45-5
Tax
TaxCr
21-1
PAT
PATCr
34-4
Growth
PAT Growth%
54.2-199.3
NPM
NPM%
10.410.6-17.8
EPS
EPS₹
3.53.7-3.4
Financial YearMar 2024Mar 2025Mar 2026
Revenue
RevenueCr
253823
Growth
Revenue Growth%
51.1-40.7
Expenses
ExpensesCr
213226
Operating Profit
Operating ProfitCr
57-4
OPM
OPM%
18.817.3-16.6
Other Income
Other IncomeCr
000
Interest Expense
Interest ExpenseCr
111
Depreciation
DepreciationCr
111
PBT
PBTCr
45-5
Tax
TaxCr
21-1
PAT
PATCr
34-4
Growth
PAT Growth%
54.2-199.3
NPM
NPM%
10.410.6-17.8
EPS
EPS₹
3.53.7-3.4

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2024Mar 2025
Equity Capital
Equity CapitalCr
912
Reserves
ReservesCr
718
Current Liabilities
Current LiabilitiesCr
2227
Non Current Liabilities
Non Current LiabilitiesCr
22
Total Liabilities
Total LiabilitiesCr
3859
Current Assets
Current AssetsCr
2745
Non Current Assets
Non Current AssetsCr
1114
Total Assets
Total AssetsCr
3859
Financial YearMar 2024Mar 2025
Equity Capital
Equity CapitalCr
912
Reserves
ReservesCr
718
Current Liabilities
Current LiabilitiesCr
2227
Non Current Liabilities
Non Current LiabilitiesCr
22
Total Liabilities
Total LiabilitiesCr
3859
Current Assets
Current AssetsCr
2745
Non Current Assets
Non Current AssetsCr
1114
Total Assets
Total AssetsCr
3859

Cash Flow

Consolidated
Standalone
Financial YearMar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-4-5-5
Investing Cash Flow
Investing Cash FlowCr
0-2-2
Financing Cash Flow
Financing Cash FlowCr
4103
Net Cash Flow
Net Cash FlowCr
04-3
Free Cash Flow
Free Cash FlowCr
-4-7
CFO To PAT
CFO To PAT%
-139.6-112.3114.4
CFO To EBITDA
CFO To EBITDA%
-77.3-69.0122.7
Financial YearMar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-4-5-5
Investing Cash Flow
Investing Cash FlowCr
0-2-2
Financing Cash Flow
Financing Cash FlowCr
4103
Net Cash Flow
Net Cash FlowCr
04-3
Free Cash Flow
Free Cash FlowCr
-4-7
CFO To PAT
CFO To PAT%
-139.6-112.3114.4
CFO To EBITDA
CFO To EBITDA%
-77.3-69.0122.7

Ratios

Consolidated
Standalone
Financial YearMar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
252634
Price To Earnings
Price To Earnings
6.3-6.4
Price To Sales
Price To Sales
0.71.11.5
Price To Book
Price To Book
0.90.90.9
EV To EBITDA
EV To EBITDA
5.1-12.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
37.435.0
OPM
OPM%
18.817.3-16.6-16.6
NPM
NPM%
10.410.6-17.8-17.8
ROCE
ROCE%
18.214.2
ROE
ROE%
17.213.8
ROA
ROA%
6.86.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
252634
Price To Earnings
Price To Earnings
6.3-6.4
Price To Sales
Price To Sales
0.71.11.5
Price To Book
Price To Book
0.90.90.9
EV To EBITDA
EV To EBITDA
5.1-12.2
Profitability Ratios
Profitability Ratios
GPM
GPM%
37.435.0
OPM
OPM%
18.817.3-16.6-16.6
NPM
NPM%
10.410.6-17.8-17.8
ROCE
ROCE%
18.214.2
ROE
ROE%
17.213.8
ROA
ROA%
6.86.8
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios

Documents — Medicamen Organics Ltd

  • Q4 FY2025 Earnings Call Transcript (Mar 2025, PDF): https://www.stockscans.in/document/iwi78wc6803go6fcrpwpzoyo.pdf
  • Q2 FY2025 Earnings Call Transcript (Sep 2024, PDF): https://www.stockscans.in/document/5mwfk7tbx5jkc169ppg0rvhz.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/kgsytu44039l6n0y1gu6goko.pdf
  • Q2 FY2026 Quarterly Result (Sep 2025, PDF): https://www.stockscans.in/document/je9a4pi1o478i7hdslohuzbw.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/ka5ccqnyqgr225srw3zu3h6l.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/orfdqd4fbvhoroop103zjaor.pdf
  • Q4 FY2025 Investor Presentation (Mar 2025, PDF): https://www.stockscans.in/document/shhrxmuju3gktfrhg1j59aeb.pdf
  • Q2 FY2025 Investor Presentation (Sep 2024, PDF): https://www.stockscans.in/document/wpqi97xn2as6axwelqea4ra9.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/klf88ty147yedu4w1tb9zssp.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/l8j19lu65hotum7oq76c09qj.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/9v31sqk9eej0i3bux4cgwza1.pdf

Concall Transcript Summaries — Medicamen Organics Ltd

  • Q4 FY2025 Concall Transcript Summary (Mar 2025): https://www.stockscans.in/company/NSE%3AMEDIORG/transcript-notes/202503/iwi78wc6803go6fcrpwpzoyo.pdf
  • Q2 FY2025 Concall Transcript Summary (Sep 2024): https://www.stockscans.in/company/NSE%3AMEDIORG/transcript-notes/202409/5mwfk7tbx5jkc169ppg0rvhz.pdf

Simplify stock analysis with powerful tools and clear insights for confident, data-driven decisions.

support@stockscans.in
© StockScans by SOIC Technologies Pvt Ltd
349 A, Lodhi Road, Punjabi Bazar, New DelhiData provided by CMOTS Internet Technologies